1. Home
  2. Analysis
  3. Kimyrsa

Kimyrsa side effects by duration, gender and age - a phase IV clinical study of FDA data

Summary:

Side effects are reported by people who take Kimyrsa. Common side effects include chills among females and chills among males.

The phase IV clinical study is created by eHealthMe based on 6 reports from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On May, 28, 2023

6 people who take Kimyrsa and have side effects are studied.

What is Kimyrsa?

Kimyrsa has active ingredients of oritavancin diphosphate. eHealthMe is studying from 6 Kimyrsa users for its effectiveness, alternative drugs and more.

Number of Kimyrsa reports submitted per year:

Kimyrsa side effects.

Kimyrsa side effects by time on the drug*:

< 1 month:

  1. Chills (felling of cold)
  2. Arthralgia (joint pain)
  3. Chest pain

1 - 6 months:

n/a

6 - 12 months:

n/a

1 - 2 years:

n/a

2 - 5 years:

n/a

5 - 10 years:

n/a

10+ years:

n/a

not specified:

  1. Chills (felling of cold)

Kimyrsa side effects by gender *:

female:

  1. Chills (felling of cold)

male:

  1. Chills (felling of cold)
  2. Arthralgia (joint pain)
  3. Chest pain

Kimyrsa side effects by age (0-1 to 60+) *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Chills (felling of cold)

60+:

  1. Arthralgia (joint pain)
  2. Chest pain

* Approximation only. Some reports may have incomplete information.

Do you take Kimyrsa?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

How the study uses the data?

The study is based on oritavancin diphosphate (the active ingredients of Kimyrsa) and Kimyrsa (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered.

Related studies

Alternative drugs to, pros and cons of Kimyrsa:

All Kimyrsa side effects from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.